InsidersTradesSigma
Follow the 신테카바이오 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 신테카바이오 has recorded 7 public disclosures. Market capitalisation: €36.6bn. The latest transaction was reported on 6 July 2026 (Purchase). Among the most active insiders: 정종선. All data is free.
4
Insider Decl.
n/a
Thresholds
n/a
3 ops.
Buy Volume
n/a
n/a
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,071 of 29,062 companies
28.6
score / 100
Value5
Quality52
FCF yld-36%
Earn yld-59%
EV/EBITDA·
ROE-59%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 July 2026
关于 신테카바이오
신테카바이오 是一家在XKRX市场上市的健康和制药领域的公司。它专注于在生物技术领域开发创新解决方案。